InvestorsHub Logo
Followers 12
Posts 896
Boards Moderated 0
Alias Born 05/29/2015

Re: None

Monday, 01/09/2017 1:12:01 PM

Monday, January 09, 2017 1:12:01 PM

Post# of 1673
Oramed is moving on to Phase 2b with an oral GLP-1 formulation in 2017, and positive results there could have the effect of reinforcing investor confidence in its technology despite Novo Nordisk pulling out of the insulin side of the equation. Novo Nordisk leaving the space could be a positive for Oramed, given that it will now have no major competitor for oral insulin, in the event that its candidate ORMD 0801 makes it to market.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ORMP News